Appharma Consulting Pty Ltd

Status: Registered
Australian Company Number: 602652826
Australian Business Number: 20602652826
Registration date: 2014-11-03
Type: Australian proprietary company
Class: Limited by Shares
Subclass: Proprietary other
last updated


Appharma Consulting Pty Ltd is a limited by shares Australian proprietary company. Located at NSW 2120 since 2014-12-01 the company is, as the updated on 2016-04-09 ABN database shows, registered. The company has been registered for Goods & Services Tax since 2014-11-03. Known company numbers for Appharma Consulting Pty Ltd are as follows: ACN - 602652826, Australian Business Number - 20602652826. Their official company name changed on 2014-11-03 to Appharma Consulting Pty Ltd. The company had used this name up until 2016-04-09. This Australian proprietary company was previously located in NSW 2120 (from 2014-11-03 to 2014-12-01). found 0 trademarks that reference the company.


Details for ABN 20602652826

Type: Australian Private Company

ABN Status

Status From To
Active 2014-11-03 current

Main Name

Name From To
Appharma Pty Ltd 2016-04-09 current
Appharma Consulting Pty Ltd 2014-11-03 2016-04-09

Main Location

Location From To
NSW 2120 2014-12-01 current
NSW 2120 2014-11-03 2014-12-01

Goods & Services Tax (GST)

Status From To
Registered 2014-11-03 current
Registered 2014-10-01 current


Find company

NSW 2120 Location

2016 © - ABN Lookup, ACN, ABR, ABN Search. All rights reserved.
Contact us:
Terms of Use and Privacy Policy

Contains public sector information licensed under the Creative Commons Attribution 3.0 Australia licence. Material on this website was obtained from publicly-accessible databases and is attributed to ©Commonwealth of Australia 2015 (, and, ©Intellectual Property Government Open Data 2015, ©ASIC - Company Register. While we try to make the information as precise and up-to-date as possible, we are aware the datasets are not always error-free. will not take responsibility for any errors in the databases. The material provided should be treated as a starting point of more in-depth research, not as fact.